AbbVie Inc (ABBV)
159.59
-7.70
(-4.60%)
USD |
NYSE |
Apr 26, 16:00
159.70
+0.11
(+0.07%)
After-Hours: 16:17
AbbVie Research and Development Expense (Quarterly): 1.927B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.927B |
| September 30, 2023 | 1.723B |
| June 30, 2023 | 1.733B |
| March 31, 2023 | 2.292B |
| December 31, 2022 | 1.79B |
| September 30, 2022 | 1.614B |
| June 30, 2022 | 1.609B |
| March 31, 2022 | 1.497B |
| December 31, 2021 | 1.827B |
| September 30, 2021 | 1.661B |
| June 30, 2021 | 1.767B |
| March 31, 2021 | 1.667B |
| December 31, 2020 | 1.712B |
| September 30, 2020 | 1.706B |
| June 30, 2020 | 1.582B |
| March 31, 2020 | 1.379B |
| December 31, 2019 | 1.542B |
| September 30, 2019 | 2.285B |
| June 30, 2019 | 1.291B |
| March 31, 2019 | 1.289B |
| December 31, 2018 | 6.495B |
| September 30, 2018 | 1.268B |
| June 30, 2018 | 1.322B |
| March 31, 2018 | 1.244B |
| December 31, 2017 | 1.408B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.228B |
| June 30, 2017 | 1.229B |
| March 31, 2017 | 1.142B |
| December 31, 2016 | 1.209B |
| September 30, 2016 | 1.106B |
| June 30, 2016 | 1.124B |
| March 31, 2016 | 946.00M |
| December 31, 2015 | 1.075B |
| September 30, 2015 | 1.418B |
| June 30, 2015 | 981.00M |
| March 31, 2015 | 811.00M |
| December 31, 2014 | 879.00M |
| September 30, 2014 | 812.00M |
| June 30, 2014 | 834.00M |
| March 31, 2014 | 772.00M |
| December 31, 2013 | 798.00M |
| September 30, 2013 | 714.00M |
| June 30, 2013 | 709.00M |
| March 31, 2013 | 634.00M |
| December 31, 2012 | 681.00M |
| September 30, 2012 | 813.00M |
| June 30, 2012 | 642.00M |
| March 31, 2012 | 642.00M |
| December 31, 2011 | 775.62M |
| September 30, 2011 | 665.52M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.291B
Minimum
Jun 2019
2.292B
Maximum
Mar 2023
1.716B
Average
1.706B
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.534B |
| Immunogen Inc (DELISTED) | 47.57M |
| Johnson & Johnson | 3.542B |
| Eli Lilly and Co | 2.563B |
| Merck & Co Inc | 9.627B |